Citadel Advisors
ARTV

Citadel Advisors’s Artiva Biotherapeutics ARTV Stock Holding History

Citadel Advisors’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$102K Buy
+15,870
New +$78.5K ﹤0.01% 12005
2025
Q4 		– Sell
-798,397
Closed -$2.29M – 14393
2025
Q3 		$2.29M Buy
798,397
+644,658
+419% +$1.72M ﹤0.01% 5804
2025
Q2 		$232K Buy
153,739
+8,650
+6% +$18.2K ﹤0.01% 10376
2025
Q1 		$435K Buy
145,089
+41,454
+40% +$224K ﹤0.01% 8782
2024
Q4 		$992K Hold
103,635
– – ﹤0.01% 7040
2024
Q3 		$1.52M Buy
+103,635
New +$1.2M ﹤0.01% 6025

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
Revelation Capital Management Sausalito, California $67.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Citadel Advisors's ARTV Position: Q1 2026 in Review

Citadel Advisors opened a new position in Artiva Biotherapeutics (ARTV) in Q1 2026: 15,870 shares worth $102K. The stake represents ﹤0.01% of the portfolio and ranks #12005 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in ARTV as recently as Q3 2025.

Citadel Advisors first reported a position in ARTV in Q3 2024 and has held it in 6 quarters since. The position peaked at $2.29M in Q3 2025. 40 funds tracked by Wall St. Rank hold ARTV as of Q1 2026.

  • Citadel Advisors held 15,870 shares of Artiva Biotherapeutics worth $102K as of Q1 2026.
  • Artiva Biotherapeutics was a new Citadel Advisors position in Q1 2026.
  • Artiva Biotherapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12005 holding.
  • Citadel Advisors first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 6 quarters since.
  • Citadel Advisors's Artiva Biotherapeutics position peaked at $2.29M in Q3 2025.
  • 40 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.